secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001193125-25-073403
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025
--------------------------------------------------------------------------------

- FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.
- Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.
- FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.
- First FB102 vitiligo patient dosing expected shortly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/0001193125-25-073403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/d876988d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-073403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer